On Tuesday, Shares of Verizon Communications Inc. (NYSE:VZ), lost -0.36% to $49.62.
Verizon Communications, has made clear what it hopes to gain with the $4.4 billion purchase of AOL: a better way to sell mobile video ads, according to Reuters.
AOL, ridiculed for its ongoing dial-up Internet business, has in the last few years assembled a set of cutting-edge online video technology tools to buy and sell ads automatically in real-time, measure audience metrics and specifically target users based on their preferences.
Such “programmatic” buying is fast becoming the most effective way for online ads to be bought and sold.
Verizon, meanwhile, has more than 100 million wireless customers and plans to launch a mobile video service that could be ad-supported, Reuters reports
Verizon Communications Inc., through its auxiliaries, provides communications, information, and entertainment products and services to consumers, businesses, and governmental agencies worldwide. The company’s Wireless segment offers wireless voice and data services; messaging services; service that enables its customers to access the Internet on smartphones, basic phones, notebook computers, and tablets; customers and business-focused multimedia offerings; location-based services; global data services; LTE Internet, a high-speed Internet service; and network access and value added services to support telemetry-type applications.
Shares of Macy’s, Inc. (NYSE:M), declined -1.06% to $65.33, during its last trading session.
Macy’s, declared that the first four pilot stores in Macy’s new off-price business, one of the company’s key growth initiatives, will open in fall 2015 in metro New York City.
To be called Macy’s Backstage, the four off-price stores will average about 30,000 square feet and offer a compelling assortment of women’s, men’s and children’s apparel, shoes, fashion accessories, housewares, home textiles, intimate apparel and jewelry. Each store also will comprise amenities, such as free WiFi and a suite of spacious fitting rooms. One location will test a café concept so customers can relax and refresh.
Merchandise will comprise clearance goods from Macy’s stores, in addition to special buys from well-recognized fashion brands – all at exceptionally great values, often between 20 percent to 80 percent off of original and comparable prices for similar merchandise.
Macy’s, Inc., together with its auxiliaries, operates stores and Internet Websites in the United States. Its stores and Websites sell a range of merchandise, counting apparel and accessories for men, women, and children; cosmetics; home furnishings; and other consumer goods.
At the end of Tuesday’s trade, Shares of Broadcom Corp. (NASDAQ:BRCM), gained 0.09% to $45.99.
Broadcom Corporation, declared it will pay its next quarterly cash dividend of $0.14 per share to holders of the Company’s common stock.
The $0.14 dividend was declared by the Board of Directors on May 12, 2015 and will be paid on June 15, 2015 to holders of record of the Company’s Class A and Class B common stock at the close of business on May 29, 2015.
Broadcom’s cash dividend policy and the payment of future cash dividends under that policy are subject to the Board’s ongoing determination that the dividend policy and the declaration of dividends are in the best interests of Broadcom’s shareholders and are in compliance with all laws and agreements of Broadcom applicable to the declaration and payment of cash dividends.
Broadcom Corporation provides semiconductor solutions for wired and wireless communications. Its products offer voice, video, data, and multimedia connectivity in the home, office, and mobile environments. The company operates in two segments: Broadband and Connectivity, and Infrastructure and Networking.
Finally, AbbVie Inc. (NYSE:ABBV), ended its last trade with -0.60% loss, and closed at $64.81.
AbbVie, declared that 18 abstracts in its gastroenterology and hepatology programs will be presented at Digestive Disease Week® (DDW) 2015, May 16 – 19, in Washington, D.C. The abstracts feature results from studies further evaluating the safety and efficacy of HUMIRA® (adalimumab) and VIEKIRA PAK™ (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets).
HUMIRA data being presented comprise a six-year observational study in patients with moderate to severe Crohn’s disease, in addition to a post hoc analysis examining durable clinical remission and response in moderate to severe ulcerative colitis. Additionally, AbbVie research analyzing the indirect costs and family burden of pediatric Crohn’s disease in the United States will be highlighted in an oral presentation. AbbVie will also present research comparing the patient burden of ulcerative colitis with Crohn’s disease, and a study evaluating ulcerative colitis severity.
HUMIRA is one of the most comprehensively studied biologics accessible and is supported by more than 12 years of physician and patient experience in inflammatory bowel diseases. In the United States, HUMIRA is approved for eight indications, counting moderate to severe Crohn’s disease in adults, moderate to severe Crohn’s disease in children 6 years of age and older and moderate to severe ulcerative colitis in adults.
Data from VIEKIRA PAK’s ongoing genotype 1 HCV development program will be presented in both oral and poster sessions throughout the meeting. The studies evaluate safety and efficacy of the regimen, with or without ribavirin, throughout diverse populations seen in clinical practice. Additionally, for the first time, a post hoc analysis of adherence rates from the Phase 3 TURQUOISE-II study in patients with cirrhosis treated with VIEKIRA PAK and ribavirin will be presented.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
